Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | ALPI | P09923 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7652331 | 0.79 | GSR (0.32) | KDM4ENPSR1L3MBTL1 | |
| SCHEMBL7642619 | 0.79 | GSR (0.32) | KDM4ENPSR1L3MBTL1 | |
| SCHEMBL29550956 | 0.72 | P2RX7 (0.36) | PTGS2PTGS1ALPLALPITLR8 | |
| SCHEMBL22775379 | 0.72 | P2RX7 (0.36) | PTGS2PTGS1ALPLALPITLR8 | |
| SCHEMBL23162752 | 0.71 | PTGS2 (0.34) | PTGS2PTGS1KDM4EALPLALPI | |
| SCHEMBL40330 | 0.69 | TRPV4 (0.42) | PTGS2PTGS1 | |
| SCHEMBL12266190 | 0.68 | TRPV1 (0.40) | PTGS2PTGS1NPSR1L3MBTL1 | |
| SCHEMBL4753484 | 0.68 | KDM4E (0.35) | KDM4ETLR8NPSR1L3MBTL1 | |
| SCHEMBL16739860 | 0.67 | HRH3 (0.31) | — | |
| SCHEMBL8878264 | 0.66 | TDP1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709501-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7335672-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1883632-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| EP-1877400-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen, Inc (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7301022-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2007-11-27 | — | — | US | disclosed |
| WO-2007076104-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070149513-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2007-06-28 | — | — | US | disclosed |
| EP-1789413-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006116563-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241296-A1 | Acute, inflammatory or neuropathic pain and inflammatory diseases such as asthma, rheumatoid arthritis, inflammatory bowel disorders, urinary incontinence, and psoriasis; e.g. 5-chloro-8-((6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-1,2,3,4-tetrahydronaphthalen-2-ol | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
| WO-2006113769-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060235036-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-10-19 | — | — | US | disclosed |
| WO-2006089311-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183745-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-08-17 | — | — | US | disclosed |
| WO-2006031852-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20060058308-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235036-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | PTGS2 175/4885PTGS1 168/4885KDM4E 4218/4885 |
| US-20060058308-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | PTGS2 183/4885PTGS1 150/4885KDM4E 3505/4885 |
| US-20060183745-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | PTGS2 175/4885PTGS1 168/4885KDM4E 4218/4885 |
| US-20070149513-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | PTGS2 183/4885PTGS1 150/4885KDM4E 3505/4885 |
| US-20060241296-A1 | Acute, inflammatory or neuropathic pain and inflammatory diseases such as asthma, rheumatoid arthritis, inflammatory bowel disorders, urinary incontinence, and psoriasis; e.g. 5-chloro-8-((6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-1,2,3,4-tetrahydronaphthalen-2-ol | TRPV1, HRH2, TRPA1 | PTGS2 16/4885PTGS1 18/4885KDM4E 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.